Rizatriptan

From Wikipedia, the free encyclopedia

Rizatriptan
Systematic (IUPAC) name
N,N-dimethyl-2- [5-(1,2,4-triazol-1-ylmethyl)- 1H-indol-3-yl]ethanamine
Identifiers
CAS number	145202-66-0
ATC code	N02CC04
PubChem	5078
DrugBank	APRD00008
Chemical data
Formula	C15H19N5
Mol. mass	269.345 g/mol
Pharmacokinetic data
Bioavailability	45%
Protein binding	14%
Metabolism	by monoamine oxidase
Half life	2–3 hours
Excretion	82% urine; 12% feces
Therapeutic considerations
Pregnancy cat.	C
Legal status
Routes	Oral

Rizatriptan (Maxalt) is a 5-HT1 agonist triptan drug developed by Merck & Co. for the treatment of migraine headaches. It is available in strengths of 5 and 10 mg as tablets and orally disintegrating tablets (Maxalt-MLT).

Maxalt obtained approval by the United States Food and Drug Administration (FDA) on June 29, 1998. It is a second-generation triptan.

Rizatriptan is available only by prescription in the United States and Canada. Similarly, it is classed as a POM (Prescription Only Medicine) in the United Kingdom and in Italy (as Rizaliv).

This medication is used to treat acute migraine attacks. It does not prevent future migraine attacks.

Indicated for:

• migraine headache with or without aura

Contraindications:

• coronary artery disease
• monoamine oxidase inhibitors

Side effects:

• Atypical sensations:
  • paresthesia

• Cardiovascular:
  • palpitations
  • syncope
  • hypertension
  • hypotension

• Ear, nose, and throat:
  • tinnitus
  • sensitivity to noise
  • sinusitis
  • allergic rhinitis
  • upper respiratory inflammation

• Gastrointestinal:
  • diarrhea

• Muscular:
  • myalgia

• Neurological:
  • phonophobia
  • photophobia

• Respiratory:
  • dyspnea

• Skin:
  • sweating

• Miscellaneous:
  • hypersensitivity

[edit] External links

• Maxalt Official homepage by Merck & Co.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.